In an embodiment, a method includes receiving, at a processor, input data from the user device and providing, via the processor, the input data as input to a machine learning model to generate an input token. The method also includes adding, via the processor, a predetermined token different from the input token to the context window based on the input meeting a criterion. The method also includes providing, via the processor, the predetermined token from the context window as input to the machine learning model to generate a response token. A response is sent to the user device based on the response token.
A method includes receiving a user input and generating a set of user input tokens based on the user input. The method also includes generating a set of enhanced input tokens by providing the set of user input tokens as input to a first machine learning model. A state is determined based on a previous state and at least one of the set of user input tokens or the set of enhanced input tokens. Predetermined data is retrieved from a database based on the state and at least one of the set of user input tokens or the set of enhanced input tokens. The method also includes generating a set of response tokens by providing the set of user input tokens and the predetermined data as input to a second machine learning model. Based on the set of response tokens, a response is sent to a user device.
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
Provided herein are compounds of Formula (I), Formula (II), Formula (III), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3, R4, RD, RG22A receptor associated diseases or disorders. (I), (II), (III).
Provided herein are compounds of Formula (I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3and R422A receptor associated diseases or disorders.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07F 9/06 - Composés du phosphore sans liaisons P—C
Provided herein are compounds of Formula (I), Formula (II), Formula (III), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3, R4, RD, RG, p and q are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I), Formula (II), Formula (III), or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.
Provided herein are compounds of Formula (I), Formula (II), Formula (III), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3, R4, RD, RG, p and q are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I), Formula (II), Formula (III), or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.
Provided herein are compounds of Formula (I),
Provided herein are compounds of Formula (I),
Provided herein are compounds of Formula (I),
a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3 and R4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
Approaches for generating predictions related to a set of input text are provided. Text can be received. A machine learning model can be utilized to determine a set of classification probabilities of the text relative to a set of anchor points. A sentiment score indicative of an emotional content of the text can be determined based, at least in part, upon a convex combination of the set of probabilities for the text. One or more predictions related to the text can be generated.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
9.
PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION
Approaches for predicting a response to an administered therapy are provided. One or more recordings of a session related to an administered therapy may be transcribed into one or more transcripts. The transcripts may be parsed into utterances. An utterance sentiment may be determined for individual utterances, and a response to the administered therapy may be predicted based, at least in part, upon the utterance sentiment.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
10.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
The present disclosure relates in one aspect to fluorinated tryptamine compounds, or analogues thereof, and compositions comprising the same. Compounds of the disclosure can be used to treat, prevent, and/or ameliorate a psychiatric disease or disorder in a subject.
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07D 209/26 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec un radical acyle lié à l'atome d'azote du cycle
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
Provided herein are compounds of Formula (I)
Provided herein are compounds of Formula (I)
Provided herein are compounds of Formula (I)
(I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R1 and R4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07D 209/14 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
Provided herein are compounds of Formula (I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R1, R2, R3and R4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT2A receptor associated diseases or disorders.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07F 7/21 - Composés cycliques ayant au moins un cycle comportant du silicium mais sans carbone dans le cycle
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
15.
METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
Approaches for generating a set of biomarkers and generating a summary and one or more recommendations based, at least in part, upon the biomarkers are provided. Sensor data associated with a user may be received. The sensor data may be analyzed to generate a set of biomarkers. One or more biomarkers of the set may be combined to generate one or more additional biomarkers. A summary and one or more recommendations may be generated based, at least in part, upon the generated set of biomarkers and the additional biomarkers. The generated summary and the one or more recommendations may be provided for display on a client device.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
Approaches for transcribing, translating, reviewing, tagging, and providing analytics for therapist sessions are provided. A media file that captures one or more interactions between one or more providers and a recipient of a service may be obtained. A transcript of at least a portion of the one or more interactions captured in the audio file may be generated. Using machine learning, a plurality of analytics may be inferred based, at least in part, upon content contained in the transcript. One or more biomarkers for the recipient may be determined based, at least in part, upon the plurality of analytics. A predicted response to the service to provide for display may be generated based, at least in part, upon the one or more biomarkers and the plurality of analytics.
G10L 25/66 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour extraire des paramètres en rapport avec l’état de santé
G06F 40/47 - Traduction assistée par ordinateur, p. ex. utilisant des mémoires de traduction
G10L 15/26 - Systèmes de synthèse de texte à partir de la parole
G10L 17/26 - Reconnaissance de caractéristiques spéciales de voix, p. ex. pour utilisation dans les détecteurs de mensongeReconnaissance des voix d’animaux
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
21.
APPARATUSES, SYSTEMS, AND METHODS FOR A REAL TIME BIOADAPTIVE STIMULUS ENVIRONMENT
Approaches for providing a real time bioadaptive stimulus environment with audio, visual, and olfactory components to enhance psychedelic therapy are provided. A virtual bioadaptive environment may be provided for experience by a user. Sensor data associated with the user may be received. The sensor data may be analyzed using at least one machine learning model to determine changes to a user state. Based at least in part upon the analyzed sensor data, modifications to be made to the virtual bioadaptive environment may be determined. A modified virtual bioadaptive environment may be provided to the user.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G06T 13/40 - Animation tridimensionnelle [3D] de personnages, p. ex. d’êtres humains, d’animaux ou d’êtres virtuels
Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.
C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application
for recording and creating audio and video files;
downloadable software in the nature of a mobile application
to record interactions and conversations between users;
downloadable software in the nature of a mobile application
for clinicians to record speech, conversation, audio, and
video in therapeutic and clinical sessions; downloadable
software to record and create audio and video files;
downloadable software to record interactions and
conversations between users; downloadable software for
clinicians to record speech, conversation, audio, and video
in therapeutic and clinical sessions. Software as a service (SaaS) services featuring software for
recording and creating audio and video files; software as a
service (SaaS) services featuring software for recording
interactions and conversations between users; software as a
service (SaaS) services featuring software for clinicians to
record speech, conversation, audio, and video in therapeutic
and clinical sessions; providing online non-downloadable
software to record and create audio and video files;
providing online non-downloadable software to record
interactions and conversations between users; providing
online non-downloadable software for clinicians to record
speech, conversation, audio, and video in therapeutic and
clinical sessions; providing technology in the nature of
online non-downloadable web-based applications that enables
users to record and create audio and video files, via a
website; providing technology in the nature of online
non-downloadable web-based applications that enables users
to record interactions and conversations between users, via
a website; providing technology in the nature of online
non-downloadable web-based applications for clinicians to
record speech, conversation, audio, and video in therapeutic
and clinical sessions, via a website.
Disclosed herein are enzymatic and modified host cell methods for prepared modified indole alkaloids. Also disclosed herein are modified indole alkaloids and their therapeutic use for treating diseases and disorders.
C12P 19/60 - Préparation d'O-glucosides, p. ex. glucosides avec un atome d'oxygène du radical saccharide lié directement à un hétérocycle autre que saccharide ou à un système cyclique condensé contenant un hétérocycle autre que saccharide, p. ex. coumermycine, novobiocine
C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle
C12P 11/00 - Préparation de composés organiques contenant du soufre
C12P 9/00 - Préparation de composés organiques contenant un métal ou un atome autre que H, N, C, O, S ou un halogène
Approaches for predicting a response to an administered therapy are provided. One or more recordings of a session related to an administered therapy may be transcribed into one or more transcripts. The transcripts may be parsed into utterances. An utterance sentiment may be determined for individual utterances, and a response to the administered therapy may be predicted based, at least in part, upon the utterance sentiment.
Approaches for generating predictions related to a set of input text are provided. Text can be received. A machine learning model can be utilized to determine a set of classification probabilities of the text relative to a set of anchor points. A sentiment score indicative of an emotional content of the text can be determined based, at least in part, upon a convex combination of the set of probabilities for the text. One or more predictions related to the text can be generated.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of mental health conditions; Pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for the treatment of mental health conditions; Pharmaceutical preparations for the treatment of mental health conditions; Pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceuticals for the treatment of mental health conditions, namely, depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders; pharmaceuticals for the treatment of depression; psychoactive medicines for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders; psychedelic medicines for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders
(2) Wearable computers in the nature of smartphones, smartglasses and activity trackers, all for monitoring and managing mental health and communicating mental health information; computer software for monitoring and managing mental health and to enable providing information in electronic form via computer and communication networks in the filed of mental health; software applications for mobile phones and tablet computers for monitoring and managing mental health and to enable providing information in electronic form via computer and communication networks in the field of mental health; wearable computers in the nature of smartphones, smartglasses and activity trackers, all for monitoring and managing depression and communicating information on depression; computer software for monitoring and managing depression and to enable providing information in electronic form via computer and communication networks in the filed of depression; software applications for mobile phones and tablet computers for monitoring and managing depression and to enable providing information in electronic form via computer and communication networks in the field of depression
(3) Medical devices and wearable medical devices, namely patient medical monitors for monitoring vital signs for monitoring and managing mental health and communicating mental health information for medical use; medical devices and wearable medical devices, namely patient medical monitors for monitoring vital signs for monitoring and managing depression and communicating information on depression for medical use; drug delivery systems consisting of subcutaneous drug delivery devices, intravenous drug delivery devices, sublingual drug delivery devices, buccal drug delivery devices, intranasal drug delivery devices, and oral tablets for delivering and administering drugs (1) Compilation and processing of data relating to mental health; compilation and processing of patient data relating to depression; promoting public awareness of mental health conditions; promoting public awareness of depression
(2) Provision of education and training in the field of mental health conditions; provision of education and training in the treatment of mental health conditions; provision of education and training in the field of depression; provision of education and training in the treatment of depression; provision of education and training in the field of psychoactive medicines and psychedelic medicines
(3) Therapy for the treatment of mental health conditions; therapy for the treatment of depression; provision of information relating to mental health and mental healthcare; provision of information relating to depression
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of mental health conditions; Pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceuticals; Pharmaceuticals for the treatment of mental health conditions; Pharmaceutical preparations for the treatment of mental health conditions; Psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Downloadable software in the nature of a mobile application for recording and creating audio and video files; downloadable software in the nature of a mobile application to record interactions and conversations between users; downloadable software in the nature of a mobile application for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; downloadable software to record and create audio and video files; downloadable software to record interactions and conversations between users; downloadable software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions. (1) Software as a service (SaaS) services featuring software for recording and creating audio and video files; software as a service (SaaS) services featuring software for recording interactions and conversations between users; software as a service (SaaS) services featuring software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; providing online non-downloadable software to record and create audio and video files; providing online non-downloadable software to record interactions and conversations between users; providing online non-downloadable software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; providing technology in the nature of online non-downloadable web-based applications that enables users to record and create audio and video files, via a website; providing technology in the nature of online non-downloadable web-based applications that enables users to record interactions and conversations between users, via a website; providing technology in the nature of online non-downloadable web-based applications for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions, via a website.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for the treatment of mental health conditions; Pharmaceutical preparations for the treatment of mental health conditions; Pharmaceutical preparations, namely, psychotropic, psychoactive, and psychedelic medicinal preparations for the treatment of mental health conditions
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention provides a novel group of active compounds based on the psychoactive compound psilocin. The psilocin derivatives provided herein exhibit improved pharmacokinetic properties during uptake as compared to psilocin, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the novel psilocin derivatives for the 5-HT2A-receptor, these derivatives are particularly advantageous for use in therapy, e.g., in the treatment of depression or drug addiction.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
41.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application
to recognize, record, transcribe, and translate speech,
conversations, and audio; downloadable software in the
nature of a mobile application to generate ready-for-review
transcriptions of speech, conversations, and audio;
downloadable software in the nature of a mobile application
using artificial intelligence (AI) to assess and analyze
data from ready-for-review transcriptions of speech,
conversations, and audio to provide insights, analytics,
metrics, and aggregate data trends; downloadable software in
the nature of a mobile application that uses artificial
intelligence (AI) for predictive analytics; downloadable
software in the nature of a mobile application using
artificial intelligence (AI) in the fields of mental health
and healthcare; downloadable software in the nature of a
mobile application to view, share, notate, and collaborate
and comment on documents; downloadable software to
recognize, record, transcribe, and translate speech,
conversations, and audio; downloadable software to generate
ready-for-review transcriptions of speech, conversations,
and audio; downloadable software using artificial
intelligence (AI) to assess and analyze data from
ready-for-review transcriptions of speech, conversations,
and audio to provide insights, analytics, metrics, and
aggregate data trends; downloadable software that uses
artificial intelligence (AI) for predictive analytics;
downloadable software using artificial intelligence (AI) in
the fields of mental health and healthcare; downloadable
software to view, share, notate, and collaborate and comment
on documents. Software as a service (SaaS) services featuring software for
recognizing, recording, transcribing, and translating
speech, conversations, and audio; software as a service
(SaaS) services featuring software for generating
ready-for-review transcriptions of speech, conversations,
and audio; software as a service (SaaS) services featuring
software using artificial intelligence (AI) to assess and
analyze data from ready-for-review transcriptions of speech,
conversations, and audio to provide insights, analytics,
metrics, and aggregate data trends; software as a service
(SaaS) services featuring software for artificial
intelligence (AI) and predictive analytics; software as a
service (SaaS) services featuring software that uses
artificial intelligence (AI) for predictive analytics;
software as a service (SaaS) services featuring software
using artificial intelligence (AI) in the fields of mental
health and healthcare; software as a service (SaaS) services
featuring software for viewing, sharing, notating, and
collaborating and commenting on documents; artificial
intelligence as a service (AIaaS) services featuring
software for predictive analytics; artificial intelligence
as a service (AIaaS) services featuring software that uses
artificial intelligence (AI) for predictive analytics;
artificial intelligence as a service (AIaaS) services
featuring software using artificial intelligence (AI) in the
fields of mental health and healthcare; providing
non-downloadable software to recognize, record, transcribe,
and translate speech, conversations, and audio; providing
non-downloadable software to generate ready-for-review
transcriptions of speech, conversations, and audio;
providing non-downloadable software using artificial
intelligence (AI) to assess and analyze data from
ready-for-review transcriptions of speech, conversations,
and audio to provide insights, analytics, metrics, and
aggregate data trends; providing non-downloadable software
for artificial intelligence (AI) and predictive analytics;
providing non-downloadable software that uses artificial
intelligence (AI) for predictive analytics; providing
non-downloadable artificial intelligence (AI) software in
the fields of mental health and healthcare; providing
non-downloadable software to view, share, notate, and
collaborate and comment on documents; providing technology
that recognizes, records, transcribes, and translates
speech, conversations, and audio via a website; providing
technology that generates ready-for-review transcriptions of
speech, conversations, and audio via a website; providing
technology that uses artificial intelligence (AI) to assess
and analyze data from ready-for-review transcriptions of
speech, conversations, and audio to provide insights,
analytics, metrics, and aggregate data trends via a website;
providing technology that uses artificial intelligence (AI)
for predictive analytics via a website; providing technology
that uses artificial intelligence (AI) in the fields of
mental health and healthcare via a website; providing
technology that enables users to view, share, notate, and
collaborate and comment on documents via a website.
43.
PSILOCYBIN AND AN ADJUNCTIVE SEROTONIN REUPTAKE INHIBITOR FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
Approaches for generating a set of biomarkers and generating a summary and one or more recommendations based, at least in part, upon the biomarkers are provided. Sensor data associated with a user may be received. The sensor data may be analyzed to generate a set of biomarkers. One or more biomarkers of the set may be combined to generate one or more additional biomarkers. A summary and one or more recommendations may be generated based, at least in part, upon the generated set of biomarkers and the additional biomarkers. The generated summary and the one or more recommendations may be provided for display on a client device.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 20/30 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies ou des activités physiques, p. ex. la physiothérapie, l’acupression ou les exercices
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
Approaches for transcribing, translating, reviewing, tagging, and providing analytics for therapist sessions are provided. A media file that captures one or more interactions between one or more providers and a recipient of a service may be obtained. A transcript of at least a portion of the one or more interactions captured in the audio file may be generated. Using machine learning, a plurality of analytics may be inferred based, at least in part, upon content contained in the transcript. One or more biomarkers for the recipient may be determined based, at least in part, upon the plurality of analytics. A predicted response to the service to provide for display may be generated based, at least in part, upon the one or more biomarkers and the plurality of analytics.
G10L 15/26 - Systèmes de synthèse de texte à partir de la parole
G10L 25/66 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour extraire des paramètres en rapport avec l’état de santé
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G10L 17/26 - Reconnaissance de caractéristiques spéciales de voix, p. ex. pour utilisation dans les détecteurs de mensongeReconnaissance des voix d’animaux
G10L 25/63 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour estimer un état émotionnel
47.
APPARATUSES, SYSTEMS, AND METHODS FOR BIOMARKER COLLECTION, BI-DIRECTIONAL PATIENT COMMUNICATION AND LONGITUDINAL PATIENT FOLLOW-UP
Approaches for generating a set of biomarkers and generating a summary and one or more recommendations based, at least in part, upon the biomarkers are provided. Sensor data associated with a user may be received. The sensor data may be analyzed to generate a set of biomarkers. One or more biomarkers of the set may be combined to generate one or more additional biomarkers. A summary and one or more recommendations may be generated based, at least in part, upon the generated set of biomarkers and the additional biomarkers. The generated summary and the one or more recommendations may be provided for display on a client device.
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 20/30 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies ou des activités physiques, p. ex. la physiothérapie, l’acupression ou les exercices
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
Approaches for transcribing, translating, reviewing, tagging, and providing analytics for therapist sessions are provided. A media file that captures one or more interactions between one or more providers and a recipient of a service may be obtained. A transcript of at least a portion of the one or more interactions captured in the audio file may be generated. Using machine learning, a plurality of analytics may be inferred based, at least in part, upon content contained in the transcript. One or more biomarkers for the recipient may be determined based, at least in part, upon the plurality of analytics. A predicted response to the service to provide for display may be generated based, at least in part, upon the one or more biomarkers and the plurality of analytics.
G10L 15/26 - Systèmes de synthèse de texte à partir de la parole
G10L 17/26 - Reconnaissance de caractéristiques spéciales de voix, p. ex. pour utilisation dans les détecteurs de mensongeReconnaissance des voix d’animaux
G10L 25/63 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour estimer un état émotionnel
G10L 25/66 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour extraire des paramètres en rapport avec l’état de santé
49.
APPARATUSES, SYSTEMS, AND METHODS FOR A REAL TIME BIOADAPTIVE STIMULUS ENVIRONMENT
Approaches for providing a real time bioadaptive stimulus environment with audio, visual, and olfactory components to enhance psychedelic therapy are provided. A virtual bioadaptive environment may be provided for experience by a user. Sensor data associated with the user may be received. The sensor data may be analyzed using at least one machine learning model to determine changes to a user state. Based at least in part upon the analyzed sensor data, modifications to be made to the virtual bioadaptive environment may be determined. A modified virtual bioadaptive environment may be provided to the user.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
50.
APPARATUSES, SYSTEMS, AND METHODS FOR A REAL TIME BIOADAPTIVE STIMULUS ENVIRONMENT
Approaches for providing a real time bioadaptive stimulus environment with audio, visual, and olfactory components to enhance psychedelic therapy are provided. A virtual bioadaptive environment may be provided for experience by a user. Sensor data associated with the user may be received. The sensor data may be analyzed using at least one machine learning model to determine changes to a user state. Based at least in part upon the analyzed sensor data, modifications to be made to the virtual bioadaptive environment may be determined. A modified virtual bioadaptive environment may be provided to the user.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
51.
TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN
The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin. The methods described herein may be used to treat subjects both responsive and unresponsive to a first dose of psilocybin.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin. The methods described herein may be used to treat subjects both responsive and unresponsive to a first dose of psilocybin.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application for recording and creating audio and video files; Downloadable software in the nature of a mobile application to record interactions and conversations between users; Downloadable software in the nature of a mobile application for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; Downloadable software to record and create audio and video files; Downloadable software to record interactions and conversations between users; Downloadable software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions Software as a service (SaaS) services featuring software for recording and creating audio and video files; Software as a service (SaaS) services featuring software for recording interactions and conversations between users; Software as a service (SaaS) services featuring software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; Providing online non-downloadable software to record and create audio and video files; Providing online non-downloadable software to record interactions and conversations between users; Providing online non-downloadable software for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions; Providing a website featuring technology that enables users to record and create audio and video files; Providing a website featuring technology that enables users to record interactions and conversations between users; Providing a website featuring technology for clinicians to record speech, conversation, audio, and video in therapeutic and clinical sessions
54.
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Downloadable software in the nature of a mobile application to recognize, record, transcribe, and translate speech, conversations, and audio; downloadable software in the nature of a mobile application to generate ready-for-review transcriptions of speech, conversations, and audio; downloadable software in the nature of a mobile application using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytic, metrics, and aggregate data trends; downloadable software in the nature of a mobile application that uses artificial intelligence (AI) for predictive analytics to improve patient care; downloadable software in the nature of a mobile application using artificial intelligence (AI) in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; downloadable software in the nature of a mobile application to view, share, notate, and collaborate and comment on documents; downloadable software to recognize, record, transcribe, and translate speech, conversations, and audio; downloadable software to generate ready-for-review transcriptions of speech, conversations, and audio; downloadable software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; downloadable software that uses artificial intelligence (AI) for predictive analytics to improve patient care; downloadable software using artificial intelligence (AI) in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; downloadable software to view, share, notate, and collaborate and comment on documents. (1) Software as a service (SaaS) services featuring software for recognizing, recording, transcribing, and translating speech, conversations, and audio; software as a service (SaaS) services featuring software for generating ready-for-review transcriptions of speech, conversations, and audio; software as a service (SaaS) services featuring software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; software as a service (SaaS) services featuring software that uses artificial intelligence (AI) for predictive analytics to improve patient care; software as a service (SaaS) services featuring software using artificial intelligence (AI) in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; software as a service (SaaS) services featuring software for viewing, sharing, notating, and collaborating and commenting on documents; artificial intelligence as a service (AIaaS) services featuring software that uses artificial intelligence (AI) for predictive analytics to improve patient care; artificial intelligence as a service (AIaaS) services featuring software using artificial intelligence (AI) in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; providing non-downloadable software to recognize, record, transcribe, and translate speech, conversations, and audio; providing non-downloadable software to generate ready-for-review transcriptions of speech, conversations, and audio; providing non-downloadable software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; providing non-downloadable software that uses artificial intelligence (AI) for predictive analytics to improve patient care; providing non-downloadable artificial intelligence (AI) software in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; providing non-downloadable software to view, share, notate, and collaborate and comment on documents; hosting a website providing users with access to technology that recognizes, records, transcribes, and translates speech, conversations, and audio content; hosting a website providing users with access to technology that generates ready-for-review transcriptions of speech, conversations, and audio content; hosting a website providing users with access to technology that uses artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio content to provide insights, analytics, metrics, and aggregate data trends; hosting a website providing users with access to technology that uses artificial intelligence (AI) for predictive analytics to improve patient care; hosting a website providing users with access to technology that uses artificial intelligence (AI) in the fields of mental health and healthcare, namely, to assist with the treatment of mental health conditions; hosting a website providing users with access to technology that enables users to view, share, notate, and collaborate and comment on documents.
57.
TREATMENT OF DEPRESSION AND OTHER VARIOUS DISORDERS WITH PSILOCYBIN
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
The present disclosure relates to fluorinated tryptamine compounds, or analogues thereof, and compositions comprising the same, that can be used to treat, prevent, and/or ameliorate a psychiatric disease or disorder in a subject.
C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application to recognize, record, transcribe, and translate speech, conversations, and audio; Downloadable software in the nature of a mobile application to generate ready-for-review transcriptions of speech, conversations, and audio; Downloadable software in the nature of a mobile application using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; Downloadable software in the nature of a mobile application that uses artificial intelligence (AI) for predictive analytics; Downloadable software in the nature of a mobile application to view, share, notate, and collaborate and comment on documents; Downloadable software to recognize, record, transcribe, and translate speech, conversations, and audio; Downloadable software to generate ready-for-review transcriptions of speech, conversations, and audio; Downloadable software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; Downloadable software that uses artificial intelligence (AI) for predictive analytics; Downloadable software to view, share, notate, and collaborate and comment on documents Software as a service (SaaS) services featuring software for recognizing, recording, transcribing, and translating speech, conversations, and audio; Software as a service (SaaS) services featuring software for generating ready-for-review transcriptions of speech, conversations, and audio; Software as a service (SaaS) services featuring software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; Software as a service (SaaS) services featuring software for use in machine learning and speech recognition using artificial intelligence (AI) and for predictive analytics; Software as a service (SaaS) services featuring software that uses artificial intelligence (AI) for predictive analytics; Software as a service (SaaS) services featuring software for viewing, sharing, notating, and collaborating and commenting on documents; Artificial intelligence as a service (AIaaS) services featuring software for predictive analytics; Artificial intelligence as a service (AIaaS) services featuring software that uses artificial intelligence (AI) for predictive analytics; Online non-downloadable software to recognize, record, transcribe, and translate speech, conversations, and audio; Online non-downloadable software to generate ready-for-review transcriptions of speech, conversations, and audio; Online non-downloadable software using artificial intelligence (AI) to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; Online non-downloadable software for use in machine learning and speech recognition using artificial intelligence (AI) and for predictive analytics; Online non-downloadable software that uses artificial intelligence (AI) for predictive analytics; Online non-downloadable software to view, share, notate, and collaborate and comment on documents; Providing a website featuring technology that enables users to recognize, record, transcribe, and translate speech, conversations, and audio; Providing a website featuring technology that enables the generation of ready-for-review transcriptions of speech, conversations, and audio; Providing a website featuring technology that uses artificial intelligence (AI) to enable users to assess and analyze data from ready-for-review transcriptions of speech, conversations, and audio to provide insights, analytics, metrics, and aggregate data trends; Providing a website featuring technology that uses artificial intelligence (AI) that enables users to conduct predictive analytics; Providing a website featuring technology that enables users to view, share, notate, and collaborate and comment on documents
62.
PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME
The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.
The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application
for users to send, receive, and access information related
to a user's health and treatment program in the field of
mental health. Software as a service (SaaS) services featuring software for
sending, receiving, and accessing information related to a
user's health and treatment program in the field of mental
health; providing online non-downloadable software for
sending, receiving, and accessing information related to a
user's health and treatment program in the field of mental
health; providing temporary use of online non-downloadable
software that allows users to send, receive, and access
information related to a user's health and treatment program
in the field of mental health via a website.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Downloadable software in the nature of a mobile application for users to send, receive, and access information related to a user's health and treatment program in the field of mental health. (1) Software as a service (SaaS) services featuring software for sending, receiving, and accessing information related to a user's health and treatment program in the field of mental health; providing online non-downloadable software for sending, receiving, and accessing information related to a user's health and treatment program in the field of mental health; providing technology in the nature of an online platform which allows users to send, receive, and access information related to a user's health and treatment program in the field of mental health via a website.
66.
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.
The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention provides a novel group of active peptide compounds based on the psychoactive safrylamine compounds MDMA, MDA, MMDA-2, and MDAI. Thereby, the invention provides for improved pharmacokinetic properties during uptake of the safrylamines, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the novel safrylamine derivatives for the 5-HT2a-receptor, the invention can find use in numerous forms of therapy, such as against depression or posttraumatic stress disorder (PTSD).
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 317/58 - Radicaux substitués par des atomes d'azote
C07D 317/70 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'oxygène comme uniques hétéro-atomes du cycle comportant les hétéro-atomes en positions 1, 3 condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques condensés avec des systèmes cycliques contenant au moins deux cycles déterminants
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/401 - ProlineSes dérivés, p. ex. captopril
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61K 31/4458 - Pipéridines non condensées, p. ex. pipérocaïne substituées uniquement en position 2, p. ex. méthylphénidate
71.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. Move particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health
conditions and disorders; psychoactive and psychedelic
medicinal preparations for the treatment of mental health
conditions and disorders. Provision of educational services, namely, training services
in the field of mental health conditions, treatment of
mental health conditions, and psychoactive medicines and
psychedelic medicines. Therapy for the treatment of mental health conditions;
provision of information relating to mental health and
mental healthcare.
74.
IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF
C07D 457/08 - Amides de l'acide lysergique dans lesquelles l'azote de l'amide est un chaînon d'un hétérocycle
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application for users to send, receive, and access information related to a user's health and treatment program in the field of mental health Software as a service (SaaS) services featuring software for sending, receiving, and accessing information related to a user's health and treatment program in the field of mental health; Providing online non-downloadable software for sending, receiving, and accessing information related to a user's health and treatment program in the field of mental health; Providing an interactive website featuring technology which allows users to send, receive, and access information related to a user's health and treatment program in the field of mental health
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceuticals for the treatment of mental health conditions and disorders; psychoactive and psychedelic medicinal preparations for the treatment of mental health conditions and disorders. (1) Provision of educational services, namely, training services in the field of mental health conditions, treatment of mental health conditions, and psychoactive medicines and psychedelic medicines.
(2) Therapy for the treatment of mental health conditions; provision of information relating to mental health and mental healthcare.
S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle
78.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
09 - Appareils et instruments scientifiques et électriques
Produits et services
Downloadable computer software for monitoring and managing mental health and communicating mental health information; Downloadable computer software applications for mobile devices for monitoring and managing mental health and communicating mental health information
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health conditions and disorders; Psychoactive and psychedelic medicinal preparations for the treatment of mental health conditions and disorders Compilation and processing of business data relating to mental health; Advertising and publicity services to promote public awareness of mental health conditions Provision of educational services, namely, training services in the field of mental health conditions, treatment of mental health conditions, and psychoactive medicines and psychedelic medicines Compiling, processing, and publishing patient data relating to mental health for the purpose of scientific and medical research Psychological therapy for the treatment of mental health conditions; Provision of information relating to mental health and mental healthcare
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Wearable computers in the nature of smartphones, smart glasses and activity trackers, all for monitoring and managing mental health and communicating mental health information Wearable medical monitors used to measure biometric data for managing mental health and communicating mental health information for medical use; Drug delivery catheters
82.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.
C12P 17/10 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health
conditions; pharmaceuticals for the treatment of depression;
psychoactive medicines; psychedelic medicines. Wearable computers in the nature of smartphones,
smartglasses and activity trackers, all for monitoring and
managing mental health and communicating mental health
information; computer software for monitoring and managing
mental health and communicating mental health information;
software applications for mobile devices for monitoring and
managing mental health and communicating mental health
information; wearable computers in the nature of
smartphones, smartglasses and activity trackers, all for
monitoring and managing depression and communicating
information on depression; computer software for monitoring
and managing depression and communicating information on
depression; software applications for mobile devices for
monitoring and managing depression and communicating
information on depression. Medical devices and wearable medical devices for monitoring
and managing mental health and communicating mental health
information; medical devices and wearable medical devices
for monitoring and managing depression and communicating
information on depression; drug delivery systems. Compilation and processing of data relating to mental
health; compilation and processing of patient data relating
to depression; promoting public awareness of mental health
conditions; promoting public awareness of depression. Provision of education and training in the field of mental
health conditions; provision of education and training in
the treatment of mental health conditions; provision of
education and training in the field of depression; provision
of education and training in the treatment of depression;
provision of education and training in the field of
psychoactive medicines and psychedelic medicines. Therapy for the treatment of mental health conditions;
therapy for the treatment of depression; provision of
information relating to mental health and mental healthcare;
provision of information relating to depression.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health
conditions; pharmaceuticals for the treatment of depression;
psychoactive medicines; psychedelic medicines. Wearable computers in the nature of smartphones,
smartglasses and activity trackers, all for monitoring and
managing mental health and communicating mental health
information; computer software for monitoring and managing
mental health and communicating mental health information;
software applications for mobile devices for monitoring and
managing mental health and communicating mental health
information; wearable computers in the nature of
smartphones, smartglasses and activity trackers, all for
monitoring and managing depression and communicating
information on depression; computer software for monitoring
and managing depression and communicating information on
depression; software applications for mobile devices for
monitoring and managing depression and communicating
information on depression. Medical devices and wearable medical devices for monitoring
and managing mental health and communicating mental health
information; medical devices and wearable medical devices
for monitoring and managing depression and communicating
information on depression; drug delivery systems. Compilation and processing of data relating to mental
health; compilation and processing of patient data relating
to depression; advertising and publicity services to promote
public awareness of mental health conditions; advertising
and publicity services to promote public awareness of
depression. Provision of education and training in the field of mental
health conditions; provision of education and training in
the treatment of mental health conditions; provision of
education and training in the field of depression; provision
of education and training in the treatment of depression;
provision of education and training in the field of
psychoactive medicines and psychedelic medicines. Therapy for the treatment of mental health conditions;
therapy for the treatment of depression; provision of
information relating to mental health and mental healthcare;
provision of information relating to depression.
87.
METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
88.
METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health conditions, namely, pharmaceuticals for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders; Psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders Wearable computers in the nature of smartphones, smart glasses and activity trackers, all for monitoring and managing mental health and communicating mental health information; Wearable computers in the nature of smartphones, smart glasses and activity trackers, all for monitoring and managing depression and communicating information on depression; Downloadable computer software for monitoring and managing depression and communicating information on depression; Downloadable computer software applications for mobile devices for monitoring and managing depression and communicating information on depression Wearable medical monitors used to measure biometric data for managing mental health and communicating mental health information for medical use; Wearable medical monitors used to measure biometric data for managing depression and communicating information on depression for medical use Advertising and publicity services to promote public awareness of mental health conditions; Advertising and publicity services to promote public awareness of depression Provision of educational services, namely, training services in the field of mental health conditions, treatment of mental health conditions, depression, treatment of depression, psychoactive medicines, and psychedelic medicines Therapy for the treatment of mental health conditions using psychoactive and psychedelic medicinal preparations, namely, therapy using psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders; Provision of information relating to mental health and mental healthcare, namely, provision of information relating to the use of psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Therapy for the treatment of mental health conditions;
therapy for the treatment of depression; provision of
information relating to mental health and mental healthcare;
provision of information relating to depression.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceuticals for the treatment of mental health conditions, namely, depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders; pharmaceuticals for the treatment of depression; psychoactive medicines for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders; psychedelic medicines for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, eating disorders, chronic pain, and brain disorders
(2) Wearable computers in the nature of smartphones, smartglasses and activity trackers, all for monitoring and managing mental health and communicating mental health information; computer software for monitoring and managing mental health and to enable providing information in electronic form via computer and communication networks in the filed of mental health; software applications for mobile phones and tablet computers for monitoring and managing mental health and to enable providing information in electronic form via computer and communication networks in the field of mental health; wearable computers in the nature of smartphones, smartglasses and activity trackers, all for monitoring and managing depression and communicating information on depression; computer software for monitoring and managing depression and to enable providing information in electronic form via computer and communication networks in the filed of depression; software applications for mobile phones and tablet computers for monitoring and managing depression and to enable providing information in electronic form via computer and communication networks in the field of depression.
(3) Medical devices and wearable medical devices, namely patient medical monitors for monitoring vital signs for monitoring and managing mental health and communicating mental health information for medical use; medical devices and wearable medical devices, namely patient medical monitors for monitoring vital signs for monitoring and managing depression and communicating information on depression for medical use; drug delivery systems consisting of subcutaneous drug delivery devices, intravenous drug delivery devices, sublingual drug delivery devices, buccal drug delivery devices, intranasal drug delivery devices, and oral tablets for delivering and administering drugs. (1) Compilation and processing of data relating to mental health; compilation and processing of patient data relating to depression; promoting public awareness of mental health conditions; promoting public awareness of depression.
(2) Provision of education and training in the field of mental health conditions; provision of education and training in the treatment of mental health conditions; provision of education and training in the field of depression; provision of education and training in the treatment of depression; provision of education and training in the field of psychoactive medicines and psychedelic medicines.
(3) Therapy for the treatment of mental health conditions; therapy for the treatment of depression; provision of information relating to mental health and mental healthcare; provision of information relating to depression.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceuticals for the treatment of mental health conditions, namely, pharmaceuticals for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders; Psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders Wearable computers in the nature of smartphones, smart glasses and activity trackers, all for monitoring and managing mental health and communicating mental health information; Wearable computers in the nature of smartphones, smart glasses and activity trackers, all for monitoring and managing depression and communicating information on depression; Downloadable computer software for monitoring and managing depression and communicating information on depression; Downloadable computer software applications for mobile devices for monitoring and managing depression and communicating information on depression Wearable medical monitors used to measure biometric data for managing mental health and communicating mental health information for medical use; Wearable medical monitors used to measure biometric data for managing depression and communicating information on depression for medical use Advertising and publicity services to promote public awareness of mental health conditions; Advertising and publicity services to promote public awareness of depression Provision of educational services, namely, training services in the field of mental health conditions, treatment of mental health conditions, depression, treatment of depression, psychoactive medicines, and psychedelic medicines Therapy for the treatment of mental health conditions using psychoactive and psychedelic medicinal preparations, namely, therapy using psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders; Provision of information relating to mental health and mental healthcare, namely, provision of information relating to the use of psychoactive and psychedelic medicinal preparations for the treatment of depression, anxiety, bipolar disorder, post-traumatic stress disorder, and eating disorders
98.
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
CA 03078765 2020-04-08(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)(19) World Intellectual PropertyOrganization 111111 111111111 111111 111 11111 1111 11111 1 11 1111 11111 1111 111 11111 1111 11111111111 1111111International Bureau (10) International Publication Number(43) International Publication Date WO 2019/073379 Al 18 April 2019 (18.04.2019) WIPO I PCT(51) International Patent Classification: Durham TS21 2JB (GB). PATIL, Hemant; c/o Aesi-CO7D 209/16 (2006.01) ca Pharmaceuticals Ltd, North Road, Queenborough KentME11 5EL (GB). NICHOLS, David; 56'702 Nash, Chapel(21) International Application Number:Hill, NC NC27517 (US).PCT/IB2018/057811(74) Agent: EQUIPPED 4 (IP) LIMITED; 4'7 Hamilton(22) International Filing Date:Square, Birkenhead Merseyside CH41 5AR (GB).09 October 2018 (09.10.2018)(81) Designated States (unless otherwise indicated, for every(25) Filing Language: Englishkind of national protection available): AE, AG, AL, AM,(26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,(30) Priority Data:DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 1716505.1 09 October 2017 (09.10.2017) GBHR, HU, ED, EL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 1810588.2 28 June 2018 (28.06.2018) GBKR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 1816438.4 09 October 2018 (09.10.2018) GBMG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,(71) Applicant: COMPASS PATHWAYS LIMITED OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,[GB/GB]; 16 Old Bailey, London Greater London EC4M SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,7EG (GB). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(72) Inventors: LONDESBROUGH, Derek John; 3'7 Linden (84) Designated States (unless otherwise indicated, for everyGrove, Hartlepool Durham T526 9QA (GB). BROWN, kind of regional protection available): ARIPO (BW, GH,Christopher; 30 Cherrytree Gardens, Gateshead Tyne and GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,Wear NE9 6TY (GB). NORTHEN, Julian Scott; 36 Hep- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,scat Terrace, South Shields Tyne and Wear NE33 4TH TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,(GB). MOORE, Gillian; 22 Matfen Court, Sedgefield EE, ES, FI, FR, GB, GR, HR, HU, EE, IS, IT, LT, LU, LV,= (54) Title: PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS = AND THEIR USEFIG 7Aog.sx'augtoN _______________________________________________________________________ 310Rat ¨=lea ¨Ak=4', A=AIr.*" ' ________________________________________ fl'Pom. Pfteui tom:40 fc.13(57) Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the " manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.[Continued on next page]CA 03078765 2020-04-08WO 2019/073379 Al HIM l0llll l llll 11111 11111 3E1111 11111111111111111111 1111111111 1101111111111111111111MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).Declarations under Rule 4.17:¨ as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700)¨ as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))Published:¨ with international search report (Art. 21(3))¨ before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))¨ in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
